Northern Trust
CUE icon

Northern Trust’s Cue Biopharma CUE Stock Holding History

Northern Trust’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.8K Sell
3,154
-211
-6% -$1.97K ﹤0.01% 4329
2025
Q4 		$30.8K Hold
3,365
– – ﹤0.01% 4348
2025
Q3 		$72.6K Sell
3,365
-1,054
-24% -$24.7K ﹤0.01% 4209
2025
Q2 		$90.5K Sell
4,419
-2,135
-33% -$45.6K ﹤0.01% 4133
2025
Q1 		$179K Sell
6,554
-386
-6% -$14.3K ﹤0.01% 3976
2024
Q4 		$227K Buy
6,940
+2,330
+51% +$87.6K ﹤0.01% 3948
2024
Q3 		$105K Sell
4,610
-7,071
-61% -$153K ﹤0.01% 4035
2024
Q2 		$435K Sell
11,681
-492
-4% -$24.3K ﹤0.01% 3554
2024
Q1 		$690K Sell
12,173
-539
-4% -$38K ﹤0.01% 3454
2023
Q4 		$1.01M Buy
12,712
+1,756
+16% +$126K ﹤0.01% 3313
2023
Q3 		$756K Sell
10,956
-92
-0.8% -$8.98K ﹤0.01% 3382
2023
Q2 		$1.21M Buy
11,048
+8,438
+323% +$992K ﹤0.01% 3284
2023
Q1 		$280K Buy
2,610
+524
+25% +$50K ﹤0.01% 3706
2022
Q4 		$178K Hold
2,086
– – ﹤0.01% 3917
2022
Q3 		$139K Buy
2,086
+70
+3% +$6.02K ﹤0.01% 4012
2022
Q2 		$150K Sell
2,016
-8,129
-80% -$951K ﹤0.01% 4026
2022
Q1 		$1.49M Sell
10,145
-404
-4% -$85.7K ﹤0.01% 3246
2021
Q4 		$3.58M Buy
10,549
+223
+2% +$86.2K ﹤0.01% 2900
2021
Q3 		$4.51M Sell
10,326
-318
-3% -$111K ﹤0.01% 2790
2021
Q2 		$3.72M Sell
10,644
-379
-3% -$147K ﹤0.01% 3014
2021
Q1 		$4.04M Sell
11,023
-435
-4% -$179K ﹤0.01% 2878
2020
Q4 		$4.3M Sell
11,458
-126
-1% -$50.3K ﹤0.01% 2769
2020
Q3 		$5.23M Sell
11,584
-123
-1% -$70.9K ﹤0.01% 2505
2020
Q2 		$8.61M Buy
11,707
+3,825
+49% +$2.77M ﹤0.01% 2192
2020
Q1 		$3.35M Buy
7,882
+546
+7% +$265K ﹤0.01% 2539
2019
Q4 		$3.49M Sell
7,336
-119
-2% -$37.4K ﹤0.01% 2798
2019
Q3 		$1.89M Buy
7,455
+636
+9% +$153K ﹤0.01% 3136
2019
Q2 		$1.84M Buy
6,819
+133
+2% +$33.1K ﹤0.01% 3120
2019
Q1 		$1.55M Buy
6,686
+367
+6% +$69.8K ﹤0.01% 3210
2018
Q4 		$891K Sell
6,319
-47
-0.7% -$8.53K ﹤0.01% 3400
2018
Q3 		$1.73M Buy
6,366
+350
+6% +$101K ﹤0.01% 3281
2018
Q2 		$2.14M Buy
6,016
+3,511
+140% +$1.4M ﹤0.01% 3177
2018
Q1 		$1.06M Buy
+2,505
New +$1.14M ﹤0.01% 3363

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

Northern Trust's CUE Position: Q1 2026 in Review

Northern Trust reduced its Cue Biopharma (CUE) stake by 6.3% in Q1 2026, selling an estimated $1.97K and leaving 3,154 shares worth $21.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4329.

Northern Trust first reported a position in CUE in Q1 2018 and has held it in 33 quarters since. The position peaked at $8.61M in Q2 2020. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • Northern Trust held 3,154 shares of Cue Biopharma worth $21.8K as of Q1 2026.
  • Northern Trust sold 211 Cue Biopharma shares in Q1 2026, an estimated $1.97K.
  • Cue Biopharma made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4329 holding.
  • Northern Trust first reported a position in Cue Biopharma in Q1 2018 and has held it in 33 quarters since.
  • Northern Trust's Cue Biopharma position peaked at $8.61M in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.